Drug Profile
Tomivosertib - Effector Therapeutics
Alternative Names: eFT-508; Tomivosertib hydrochlorideLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Effector Therapeutics
- Developer eFFECTOR Therapeutics; Medpace; Merck AG; Northwestern University; Pfizer
- Class Antineoplastics; Cyclohexanes; Imidazoles; Immunotherapies; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cancer; Colorectal cancer; Diffuse large B cell lymphoma; Liver cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
- Phase I Acute myeloid leukaemia
- No development reported Breast cancer
Most Recent Events
- 24 Oct 2023 Preclinical trials in Acute myeloid leukaemia in USA (PO) before October 2023
- 24 Oct 2023 eFFECTOR Therapeutics and Northwestern University agree to co-develop tomivosertib in USA for Acute myeloid leukemia
- 24 Oct 2023 Pharmacodynamics data from a preclinical trial in Cancer released by eFFECTOR Therapeutics